House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Nephrology · Rheumatology

ANCA-associated vasculitis

KDIGO · 2024 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

KDIGO 2024 updates kidney-focused management of ANCA-associated vasculitis, including the role of rituximab, cyclophosphamide, avacopan and selected use of plasma exchange. Rapidly deteriorating patients with a compatible presentation and MPO/PR3 positivity should not wait for biopsy reporting before treatment. Remission induction must be followed by individualized maintenance, relapse surveillance and infection prevention. Practice points supplement graded recommendations and should retain their conditional wording.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Start urgent specialist care without avoidable delay

  • When the presentation fits small-vessel vasculitis and MPO- or PR3-ANCA is positive, do not wait for kidney biopsy or its report before starting immunosuppression, particularly with rapid deterioration. Obtain biopsy when feasible within the specialist diagnostic pathway. [1]
  • Manage ANCA-associated vasculitis in a centre experienced in the condition. Diagnostic and treatment decisions should take account of disease activity across organs, not kidney laboratory values alone. [1]
  • ANCA persistence, rising titres or conversion from negative to positive may signal relapse risk, but these changes are only modest predictors. Use them to inform clinical assessment rather than as a stand-alone reason for treatment changes. [1]

Induce remission according to severity and treatment risks

  • For new-onset disease, KDIGO recommends glucocorticoids together with rituximab or cyclophosphamide as initial therapy. This is a strong recommendation with moderate-certainty evidence, graded 1B. [1]
  • With markedly reduced or rapidly declining kidney function and serum creatinine above 4 mg/dl, evidence for rituximab plus glucocorticoids alone is limited. Consider cyclophosphamide with glucocorticoids, or a rituximab–cyclophosphamide combination. [1]
  • Rituximab may be favored for children or adolescents, fertility concerns, frail older adults, relapsing or PR3-positive disease, and when glucocorticoid sparing is particularly important. Severe glomerulonephritis favors considering cyclophosphamide. [1]
  • Avacopan may replace glucocorticoids as part of induction, with the greatest potential benefit in people at increased steroid-toxicity risk. It accompanies rituximab or cyclophosphamide rather than replacing the induction immunosuppressant. [1]
  • Consider stopping immunosuppressive therapy after 3 months when the patient remains dialysis-dependent and has no extrarenal disease manifestations. Both conditions matter; dialysis alone is not the stated criterion. [1]

Use plasma exchange for specified high-risk settings

  • Consider plasma exchange with serum creatinine above 3.4 mg/dl, dialysis requirement or rapidly increasing creatinine, or diffuse alveolar haemorrhage accompanied by hypoxaemia. This is a consideration, not routine treatment for every patient. [1]
  • Add plasma exchange in an overlap syndrome of ANCA-associated vasculitis and anti-glomerular-basement-membrane disease. [1]

Consolidate remission and plan withdrawal cautiously

  • After remission induction, use either maintenance rituximab, or azathioprine together with low-dose glucocorticoids; KDIGO grades this 1C. Most patients induced with rituximab should still receive maintenance immunosuppression. [1]
  • The stated optimal remission-maintenance duration ranges from 18 months to 4 years after induction. When considering withdrawal, assess relapse risk and teach patients to seek prompt assessment if symptoms recur. [1]
  • If azathioprine is not tolerated, consider mycophenolate or methotrexate for maintenance. Do not use methotrexate when GFR is below 60 ml/min/1.73 m². [1]
  • For maintenance selection, relapsing or PR3-positive disease, frailty, steroid-sparing needs or azathioprine allergy favor rituximab. Baseline IgG below 300 mg/dl or limited rituximab availability favor considering azathioprine. [1]

Reassess relapse, refractory disease and transplant timing

  • Reinduce remission in relapsing disease, preferably with rituximab. For refractory disease, options include increasing glucocorticoids or adding rituximab after cyclophosphamide induction, or vice versa; plasma exchange can be considered. [1]
  • Delay kidney transplantation until complete clinical remission has lasted at least 6 months. Persistent ANCA positivity alone should not delay transplantation. [1]

Prevent infection and monitor immune effects

  • Provide low-dose trimethoprim–sulfamethoxazole or an alternative for Pneumocystis prophylaxis throughout cyclophosphamide treatment or for 6 months after rituximab induction. Consider longer prophylaxis with repeated rituximab, structural lung disease or ongoing immunosuppressive or glucocorticoid therapy. [1]
  • Measure IgG before rituximab and every 6 months during treatment. Low baseline IgG can indicate greater secondary-immunodeficiency risk. [1]

Limitations and use

  • This summary does not reproduce complete induction dosing, age and kidney-function dose reductions, glucocorticoid taper schedules or maintenance infusion regimens.
  • Creatinine decision thresholds here are expressed in mg/dl. SI-unit thresholds are not reproduced.
  • The guidance is principally kidney-focused; organ-specific differential diagnosis, infection screening and individual drug contraindications require the full specialist assessment.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    ANCA-associated vasculitis

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
KDIGO
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Start urgent specialist care without avoidable delay
  • Induce remission according to severity and treatment risks
  • Use plasma exchange for specified high-risk settings
  • Consolidate remission and plan withdrawal cautiously
  • Reassess relapse, refractory disease and transplant timing
  • Prevent infection and monitor immune effects
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House